Renewal by Andersen Launches Ensemble™ Entry Door Designer Collection
COTTAGE GROVE, Minn., May 1, 2025 /PRNewswire/ — Renewal by Andersen, the nation's best window and door replacement solution*, is excited to announce the nationwide launch of the new Ensemble™ Entry Door Designer Collection.
Developed in collaboration with Renewal by Andersen's expert Brand Ambassadors, this premium collection of ready-to-order designs follows the successful introduction of the company's entry door portfolio in 2024. Homeowners can now choose from a curated selection from the designer collection and if desired, they can further customize their door from an array of color, hardware and glass choices, all designed to enhance curb appeal, increase home value, and provide superior security and energy efficiency.
'We've been transforming homes and enhancing curb appeal with superior replacement windows for 30 years. Last year, we introduced our first entry door product, and now, we are excited to enhance this offering with the launch of the Ensemble Entry Door Designer Collection. This new, collection makes it even easier for homeowners to refresh their homes,' said Troy Barrow, President of Renewal by Andersen. 'We are proud to introduce a premium entry door offering that combines beauty, durability, and personalization, whether looking to match an existing door or elevate a home with a statement entry. Each door design allows homeowners to create an entryway that reflects their personal style while benefiting from Renewal by Andersen's trusted craftsmanship and world-class service.'
Designed by Experts, Inspired by You The new designer Collection features curated design combinations selected by Renewal by Andersen's Brand Ambassadors: Breegan Jane, Laurie March, Darren Keefe, Will Taylor and Liz Marie Galvan. These renowned designers drew from their extensive experience in remodeling, design and construction to contribute three unique entry door designs each, ranging from classic elegance to bold contemporary aesthetics. Each door design makes a lasting first impression, offering superior craftsmanship and premium materials tailored to every home.
With these pre-configured designer options, homeowners can easily select from a professionally curated collection or further personalize their door by adjusting colors, hardware, and stylistic elements during an in-home consultation. With thousands of design possibilities, homeowners can design their dream door with the help of Renewal by Andersen Brand Ambassador designers, bringing their vision to life. Alternatively, homeowners can truly customize their door from the ground up by choosing colors, hardware, and stylistic elements to create a unique design that reflects their personal style.
The collections embody a blend of style and functionality, as highlighted by Breegan Jane, designer, TV personality and creator of the Radiant design.
'I wanted my new door to match my Renewal by Andersen® Acclaim™ windows for a seamless design. The door design I selected had the same picture frame-reminiscent style as the rest of the home. I enclosed the glass door with two sidelights and a transom. My goal was to utilize as much natural light as possible, and this design allows me to create more visual space,' said Breegan Jane.
The Ensemble™ Entry Door Portfolio The Renewal by Andersen® Ensemble entry door portfolio features an array of options that combine superior performance, aesthetic appeal and enhanced security. The portfolio offers a variety of options to suit different home layouts and preferences, such as:
Single Entry Doors: Space-saving elegance with excellent insulation.
Single Entry Doors with Sidelights: A touch of natural light for a welcoming feel.
Double Entry Doors: Grand and symmetrical for larger home entrances.
Multiple Grille, Glass and Hardware Options: Over 38 styles and 20 color choices for maximum personalization.
Combining beauty, durability and enhanced security, Ensemble entry doors withstand the test of time* while enhancing your home's curb appeal. To learn more about Ensemble entry doors visit RenewalByAndersen.com or schedule a consultation here.
About Renewal by Andersen
Renewal by Andersen LLC is the start-to-finish window replacement division of Andersen Corporation, winner of the U.S. Environmental Protection Agency's 2024 ENERGY STAR® Partner of the Year – Sustained Excellence Award. Renewal by Andersen offers a replacement process that includes an in-home consultation, custom manufacturing, and installation through one of the largest nationwide networks of window replacement specialists. For a complimentary in-home consultation, or to view more information about Renewal by Andersen visit www.renewalbyandersen.com.
Renewal by Andersen received the highest number of awards among the Window and Patio Doors Retailer and Manufacturer segments over the last eighteen years total as compared to all other brands in the J.D Power U.S. Window and Patio Door Satisfaction Studies, measuring customers' satisfaction with their windows and/or patio doors purchase. Visit jdpower.com for award information.
*See the limited warranty for details
'Renewal by Andersen' and all other marks where denoted are trademarks of Andersen Corporation.
© 2025 Andersen Corporation. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Kelley Blue Book, Experian Team Up to Bring Buyers Better Vehicle History Reports
Unmatched Trust and Transparency from Detailed Reports to Boost Buyer Confidence and Drive More Conversions ATLANTA and COSTA MESA, Calif., June 10, 2025 /PRNewswire/ — As the market heats up, along with the competition, it has never been more important to make smart car buying choices based on trusted research. As part of its commitment to drive stronger results for our clients, Kelley Blue Book and Autotrader, Cox Automotive brands, today announced they are expanding their strategic relationship with Experian, a global data and technology company, to co-brand its AutoCheck® vehicle history reports on and vehicle listings. Experian's AutoCheck vehicle history reports offered by Kelley Blue Book combine the power of the storied and trusted Kelley Blue Book brand with the detailed insights Experian already delivers to car buyers and sellers for more efficient decision-making. Experian's AutoCheck vehicle history reports will be available on all eligible listings on both Kelley Blue Book and Autotrader, allowing dealerships to provide potential buyers with detailed vehicle history information and inherent trust in their product. Featured on the vehicle history reports, the proprietary AutoCheck Score offers a quick, clear snapshot of a vehicle's predicted reliability, helping buyers and sellers feel confident every step of the way. 'With proprietary auction data and backed by Kelley Blue Book, the No. 1 trusted automotive brand for shoppers planning to buy in the next six months, dealerships can gain the edge they need to better buy and sell inventory,' said Jessica Stafford, senior vice president, consumer solutions, at Cox Automotive. 'Our clients and consumers will have detailed information to make informed car-buying decisions which, given the current market, is more important than ever before. Increased transparency leads to more confident and informed shopper decisions, and ultimately, more leads for dealers.' Dealerships also benefit from more engagement in listings, reporting with an extensive database of automotive records, and easy-to-understand insights to better compare a vehicle to other similar models currently on the market. In fact, free Experian vehicle history reports drive 44% more lead conversions on Autotrader vehicle detail pages than the leading competitor. * 'Researching and comparing vehicle listings is a critical step in the used car buying experience. Nearly every in-market shopper scours every ounce of information available to help them choose the right vehicle,' said Robert Granados, president of Experian Automotive. 'By joining forces with Kelley Blue Book, we're able to put information about a vehicle's history directly into the hands of more consumers. Now, in-market shoppers will have more transparency when buying a vehicle and feel more confident in their choice.' For more information about Experian AutoCheck offered by Kelley Blue Book, contact your Kelley Blue Book or Autotrader sales representative. *Based on internal analysis of vehicle history report leads submitted from Autotrader listings/VDPs from Dec 2024 – May 2025. Individual results may vary. About Kelley Blue Book Founded in 1926, Kelley Blue Book, The Trusted Resource®, is the vehicle valuation and information source trusted and relied upon by both consumers and the automotive industry for nearly a century. As the industry standard for generations, Kelley Blue Book provides transparent, objective information and data-driven, innovative tools for consumers, automotive dealers and manufacturers. Kelley Blue Book publishes millions of market-reflective values weekly on its top-rated website from its famous Blue Book® Trade-In Values to the Kelley Blue Book® Price Advisor tool, which offers a range for what consumers reasonably can expect to pay for a vehicle in their area. editors rate and review hundreds of new vehicles each year to help consumers understand the Best Cars and Best SUVs to meet their needs. Kelley Blue BookSM Instant Cash Offer provides a redeemable trade-in offer to transaction-ready consumers and conveniently connects them to local participating dealers. Kelley Blue Book's Service Advisor provides guidance on how much to pay for service and repairs, allowing consumers to schedule service with local dealers on Kelley Blue Book also provides vehicle values to finance and insurance companies as well as governmental agencies. Kelley Blue Book is a Cox Automotive brand. About Cox AutomotiveCox Automotive is the world's largest automotive services and technology provider. Fueled by the largest breadth of first-party data fed by 2.3 billion online interactions a year, Cox Automotive tailors leading solutions for car shoppers, auto manufacturers, dealers, lenders and fleets. The company has 29,000+ employees on five continents and a portfolio of industry-leading brands that include Autotrader®, Kelley Blue Book®, Manheim®, vAuto®, Dealertrack®, NextGear Capital™, CentralDispatch® and FleetNet America®. Cox Automotive is a subsidiary of Cox Enterprises Inc., a privately owned, Atlanta-based company with $23 billion in annual revenue. Visit or connect via @CoxAutomotive on X, CoxAutoInc on Facebook or Cox-Automotive-Inc on LinkedIn. About ExperianExperian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money. We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments. We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 23,300 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Sumsub Upgrades Case Management Solution with AI Assistant for FinCrime Teams
LONDON, June 10, 2025 /PRNewswire/ — Sumsub, a global verification leader, has announced a major AI-powered update to its Case Management solution—a ready-to-use, cross-functional hub for financial crime investigations designed to streamline fragmented risk operations. Built with direct input from fincrime teams and Sumsub clients, the new release introduces AI-driven tools and intelligent automation to help investigators act on risk in real time. The new Case Management solution provides a unified workspace for cross-functional teams, centralizing identity information, payment histories, risk scores, and internal audit notes in one intelligent interface. One of the key features of this upgrade is Summy, Sumsub's new AI Assistant, which provides case summaries and action recommendations for risk, compliance, and fraud teams. Summy gives investigators the full context of each case—covering user background, transaction history, behavioral insights, and more—while suggesting smart next steps to accelerate decision-making. Case Management is included as a core feature across Sumsub's identity verification, anti-fraud, and AML solutions—fully integrated and ready to deploy without complex adoption procedures. This launch comes as financial crime teams face increasingly complex threats. The global average fraud rate surged by 30% year-over-year—from 2.0% in 2024 to 2.6% in 2025 – driven by deepfakes, fraud-as-a-service, and rapidly evolving typologies. Teams must act faster, smarter, and more collaboratively than ever before. Apart from Summy, AI assistant key features include: Pre-built, customizable workflow templates ('Case Blueprints') that can be set up and used straight away Unified access to applicant data, documents, AML flags, and payments—removes silos and accelerates investigations Custom case views and role-based access control tailors visibility of data and sensitive information, with ability to easily move responsibilities and access around team members Real-time risk updates ensure every decision reflects the latest user behavior and transaction patterns Fraud Network Detection uses AI to uncover hidden connections between suspicious users and real–behaviors 'Fragmentation is one of the biggest threats in modern risk management,' said Andrew Novoselsky, Chief Product Officer at Sumsub. 'With the rise of deepfakes and complex fraud schemes, teams can't afford to work in silos. That's why we built a platform that's not just unified, but smart—where AI like Summy supports every step of the investigation. This is a leap forward in making compliance faster, clearer, and more effective. Tested extensively by Sumsub's Quality Control Team, and built on extensive research into fincrime teams and insights gathered during our Customer Advisory Board meetings, this solution was built to address the most pressing challenges in case management. It makes investigations faster, more transparent, and easier to manage for fraud and risk professionals.' To explore the new Case Management solution, visit: About Sumsub Sumsub is a full-cycle verification platform that secures the whole user journey. With Sumsub's customizable KYC, KYB, Transaction Monitoring, and Fraud Prevention solutions, you can orchestrate your verification process, welcome more customers worldwide, meet compliance requirements, reduce costs, and protect your business. Sumsub has over 4,000 clients across the fintech, crypto, transportation, trading, e-commerce, education, and gaming industries, including Bitpanda, Wirex, Avis, Bybit, Vodafone, Duolingo, Kaizen Gaming, and TransferGo. Sumsub has citations in research published by global institutions such as the United Nations and Statista, as well as ongoing consultancy and engagements with INTERPOL.
